Medical Device News Magazine

Vigilant Biosciences Debuts the Revolutionary BeVigilant OraFusion System in the UK

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Vigilant Biosciences, Inc. (“Vigilant”), an innovator and creator of solutions aimed at facilitating the early detection of oral cancer, is proud to announce the launch of its transformative product, the BeVigilant OraFusion System, in the United Kingdom.

The BeVigilant OraFusion System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors. Detecting oral cancer in its infancy, particularly during Stage 1 or Stage 2, can dramatically improve outcomes, increasing survival rates to an impressive 90%. The current survival rate for oral cancer is 50%, predominantly due to delayed detection and intervention.

Despite oral cancer often presenting early symptoms, current dental screening limitations hinder early diagnosis. Healthcare practitioners, while diligent, may find early malignancy identification challenging, occasionally defaulting to a cautious approach. Late-stage diagnoses often necessitate extensive surgery, impacting quality of life. However, technological advancements in diagnostic methods, like the BeVigilant OraFusion System, empower practitioners to enhance early detection and dramatically improve their accuracy in assessing patients.

“Our mission revolves around elevating survival outcomes in oral cancer through early detection,” expressed Bill Brodie, CEO of Vigilant Biosciences. “The introduction of the BeVigilant OraFusion System to the UK market is a manifestation of our mission, to save lives through early detection, bringing renewed hope to those impacted by this disease.”

In its ongoing battle against oral cancer, Vigilant Biosciences perpetuates its commitment to developing straightforward, accurate and economical solutions, empowering healthcare practitioners to transform lives through timely intervention. For additional information about Vigilant Biosciences and its innovative products, please visit www.vigilantbiosciences.com .

Note: The BeVigilant OraFusion System is not available for sale in the U.S.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”